Why the study?
What is the role of coagulation factors and platelets in the pathogenesis of pulmonary hypertension, and what is the potential role of anticoagulants in its therapy?
What is the role of coagulation factors and platelets in the pathogenesis of pulmonary hypertension, and what is the potential role of anticoagulants in its therapy?
This review highlights the role of coagulation factors and platelets in pulmonary hypertension and discusses the potential therapeutic role of warfarin and novel oral anticoagulants.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for anticoagulation in pulmonary hypertension; prospective trials needed before clinical adoption.
This article is intended to deliver a clinically relevant overview about the role of coagulation factors and platelets in the pathogenesis of pulmonary hypertension. After summarizing the available data with warfarin, some information is provided about the novel oral anticoagulants that were recently approved for atrial fibrillation and may soon be approved for venous thrombosis. The author is hopeful that this information will stimulate investigator interest in this topic and drive us toward meaningful studies about this important aspect of PAH therapy.
No takes yet. Share an insight, caveat, or question.
R. James White (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: